Seroprevalence of neutralizing antibodies to adenovirus type 5 among children in India: Implications for recombinant adenovirus-based vaccines

Clinical and Vaccine Immunology

Volumn 14, Issue 8, 2007, Pages 1053-1055

  Appaiahgari, Mohan Babu ^a   Pandey, Ravindra Mohan ^b   Vrati, Sudhanshu ^a,c  

^a NATIONAL INSTITUTE OF IMMUNOLOGY   (India)

^b ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^c JAWAHARLAL NEHRU UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTRALIZING ANTIBODY; RECOMBINANT VACCINE; VIRUS ANTIBODY; VIRUS VACCINE;

ADENOVIRUS 5; AGE DISTRIBUTION; ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HOST RESISTANCE; HUMAN; IMMUNIZATION; INDIA; INFANT; MAJOR CLINICAL STUDY; MALE; NEWBORN; PRESCHOOL CHILD; PRIORITY JOURNAL; SEROPREVALENCE; VIRUS INFECTION; AGE; BLOOD; CLASSIFICATION; GENETICS; HUMAN ADENOVIRUS; IMMUNOLOGY; SERODIAGNOSIS; SEROTYPING; VIROLOGY;

ADENOVIRUS INFECTIONS, HUMAN; ADENOVIRUSES, HUMAN; AGE FACTORS; ANTIBODIES, VIRAL; CHILD, PRESCHOOL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; INDIA; INFANT; INFANT, NEWBORN; NEUTRALIZATION TESTS; SEROTYPING; VACCINES, SYNTHETIC; VIRAL VACCINES;

EID: 35248871667     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00173-07     Document Type: Article

References (21)

1. Appaiahgari, M. B., M. Saini, M. Rauthan, Jyoti, and S. Vrati. 2006. Immunization with recombinant adenovirus synthesizing the secretory form of Japanese encephalitis virus envelope protein protects adenovirus-exposed mice against lethal encephalitis. Microbes Infect. 8:92-104.
2. Barratt-Boyes, S. M., A. C. Soloff, W. Gao, E. Nwanegbo, X. Liu, P. A. Rajakumar, K. N. Brown, P. D. Robbins, M. Murphey-Corb, R. D. Day, and A. Gambotto. 2006. Broad cellular immunity with robust memory responses to simian immunodeficiency virus following serial vaccination with adenovirus 5- and 35-based vectors. J. Gen. Virol. 87:139-149.
3. Bauer, U., G. Flunker, K. Bruss, K. Kallwellis, H. Liebermann, T. Luettich, M. Motz, and W. Seidel. 2005. Detection of antibodies against adenovirus protein IX, fiber, and hexon in human sera by immunoblot assay. J. Clin. Microbiol. 43:4426-4433.
4. D'Ambrosio, E., N. Del Grosso, A. Chicca, and M. Midulla. 1982. Neutralizing antibodies against 33 human adenoviruses in normal children in Rome. J. Hyg. (London) 89:155-161.
5. Gaden, F., L. Franqueville, M. K. Magnusson, S. S. Hong, M. D. Merten, L. Lindholm, and P. Boulanger. 2004. Gene transduction and cell entry pathway of fiber-modified adenovirus type 5 vectors carrying novel endocytic peptide ligands selected on human tracheal glandular cells. J. Virol. 78:7227-7247.
6. Glasgow, J. N., E. J. Kremer, A. Hemminki, G. P. Siegal, J. T. Douglas, and D. T. Curiel. 2004. An adenovirus vector with a chimeric fiber derived from canine adenovirus type 2 displays novel tropism. Virology 324:103-116.
7. Gomez-Roman, V. R., R. H. Florese, B. Peng, D. C. Montefiori, V. S. Kalyanaraman, D. Venzon, I. Srivastava, S. W. Barnett, and M. Robert-Guroff. 2006. An adenovirus-based HIV subtype B prime/boost vaccine regimen elicits antibodies mediating broad antibody-dependent cellular cytotoxicity against non-subtype B HIV strains. J. Acquir. Immune. Defic. Syndr. 43:270-277.
8. Henning, P., K. M. Andersson, K. Frykholm, A. Ali, M. K. Magnusson, P. A. Nygren, O. Granio, S. S. Hong, P. Boulanger, and L. Lindholm. 2005. Tumor cell targeted gene delivery by adenovirus 5 vectors carrying knobless fibers with antibody-binding domains. Gene Ther. 12:211-224.
9. Hong, S. S., N. A. Habib, L. Franqueville, S. Jensen, and P. A. Boulanger. 2003. Identification of adenovirus (Ad) penton base neutralizing epitopes by use of sera from patients who had received conditionally replicative Ad (Addl1520) for treatment of liver tumors. J. Virol. 77:10366-10375.
10. Kostense, S., W. Koudstaal, M. Sprangers, G. J. Weverling, G. Penders, N. Helmus, R. Vogels, M. Bakker, B. Berkhout, M. Havenga, and J. Goudsmit. 2004. Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector. AIDS 18:1213-1216.
11. Malkevitch, N., L. J. Patterson, K. Aldrich, E. Richardson, W. G. Alvord, and M. Robert-Guroff. 2003. A replication competent adenovirus 5 host range mutant-simian immunodeficiency virus (SIV) recombinant priming/subunit protein boosting vaccine regimen induces broad, persistent SIVspecific cellular immunity to dominant and subdominant epitopes in Mamu-A*01 rhesus macaques. J. Immunol. 170:4281-4289.
12. Mathur, A., G. Singh, U. K. Singh, R. M. Mehrotra, and U. C. Chaturvedi. 1978. Prevalence of neutralizing antibodies against adenoviruses at Lucknow. Indian J. Med. Res. 67:19-26.
13. Nishio, O., K. Matsui, K. T. Goh, Y. Matsunaga, and S. Inouye. 2001. Prevalence of adenovirus types 3 and 7 antibodies in Singapore. Jpn. J. Infect. Dis. 54:128-129.
14. Nwanegbo, E., E. Vardas, W. Gao, H. Whittle, H. Sun, D. Rowe, P. D. Robbins, and A. Gambotto. 2004. Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States. Clin. Diagn. Lab. Immunol. 11:351-357.
15. Piedra, P. A., G. A. Poveda, B. Ramsey, K. McCoy, and P. W. Hiatt. 1998. Incidence and prevalence of neutralizing antibodies to the common adenoviruses in children with cystic fibrosis: implication for gene therapy with adenovirus vectors. Pediatrics 101:1013-1019.
16. Roth, D. A., M. D. McKirnan, I. Canestrelli, M. H. Gao, N. Dalton, N. C. Lai, D. M. Roth, and H. K. Hammond. 2006. Intracoronary delivery of an adenovirus encoding fibroblast growth factor-4 in myocardial ischemia: effect of serum antibodies and previous exposure to adenovirus. Hum. Gene Ther. 17:230-238.
17. Sullivan, N. J., A. Sanchez, P. E. Rollin, Z. Y. Yang, and G. J. Nabel. 2000. Development of a preventive vaccine for Ebola virus infection in primates. Nature 408:605-609.
18. Thorner, A. R., R. Vogels, J. Kaspers, G. J. Weverling, L. Holterman, A. A. Lemckert, A. Dilraj, L. M. McNally, P. M. Jeena, S. Jepsen, P. Abbink, A. Nanda, P. E. Swanson, A. T. Bates, K. L. O'Brien, M. J. Havenga, J. Goudsmit, and D. H. Barouch. 2006. Age dependence of adenovirus-specific neutralizing antibody titers in individuals from sub-Saharan Africa. J. Clin. Microbiol. 44:3781-3783.
19. Toogood, C. I., J. Crompton, and R. T. Hay. 1992. Antipeptide antisera define neutralizing epitopes on the adenovirus hexon. J. Gen. Virol. 73:1429-1435.
20. Tursz, T., A. L. Cesne, P. Baldeyrou, E. Gautier, P. Opolon, C. Schatz, A. Pavirani, M. Courtney, D. Lamy, T. Ragot, P. Saulnier, A. Andremont, R. Monier, M. Perricaudet, and T. Le Chevalier. 1996. Phase I study of a recombinant adenovirus-mediated gene transfer in lung cancer patients. J. Natl. Cancer Inst. 88:1857-1863.
21. Wu, H., I. Dmitriev, E. Kashentseva, T. Seki, M. Wang, and D. T. Curiel. 2002. Construction and characterization of adenovirus serotype 5 packaged by serotype 3 hexon. J. Virol. 76:12775-12782.